We were there at the early stages of Antibody Drug Conjugates (ADCs) and have carefully studied the innovations done so far. We questioned the fundamentals to understand why there is such a high failure rate due to toxicity for ADCs going into the clinic. Aarvik was built around the basis of trying to answer these fundamental questions.

Aarvik is addressing ways to improve the efficacy and safety of Immune Cell Engagers (ICEs).